Tuesday, February 13, 2018 10:15 PM ET
Insiders Make Significant Stock buys in Miragen Therapeutics (MGEN) Shares Reversing the prior 90 day Trend
There were substantial insider purchases of Miragen Therapeutics shares today, as revealed in filings with the SEC as two insiders — Bruce Booth, Director, and Adam Scott Levy, Officer — bought 554,544 shares in the company having a net market value of approximately $3,049,992. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 12,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 542,544 shares and have averaged 188,848 shares per transaction over this time period.
Miragen Therapeutics insider trading represents a level of buy/sell trades that is above for the 191 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 164 buy/sell trades during this period for an average of 0.9 transactions per company. The number of shares per buy/sell trade for Miragen Therapeutics insiders was also higher. Within the peer group there were 14,907,330 shares purchased and 12,685,407 shares sold with company insiders having bought 19,839 shares on average.
The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Today’s Insider Activity
* Bruce Booth, Director, bought 545,454 shares
* Adam Scott Levy, Officer, bought 9,090 shares
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2018 UpTick Data Technologies. All rights reserved.